Company / Return on Equity (ROE)
LIGAND PHARMACEUTICALS INC Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
12.2%
FY2025
5-year range
-5.6% / 12.2%
FY2021-FY2025
Trend
+2595.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Equity (ROE) changed +2596% YoY in FY2025, a notable deviation from the 9-year average annual change of +654%.
Based on SEC 10-K filings.
12.2% in FY2025 with a 5-year CAGR of +12.7%.
Improved from 7.4% to 12.2% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +17.8pp
- 5-Year Change
- +12.7pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 2595.9% year-over-year.
- Peak return on equity (roe) was recorded in FY2019.
- Lowest return on equity (roe) in the period was in FY2022.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 12.2% | +2595.9% |
| FY2024 | -0.5% | -106.6% |
| FY2023 | 7.4% | +233.3% |
| FY2022 | -5.6% | -180.2% |
| FY2021 | 7.0% | +1757.1% |
| FY2020 | -0.4% | -100.5% |
| FY2019 | 82.0% | +221.0% |
| FY2018 | 25.6% | +713.7% |
| FY2017 | 3.1% | +754.2% |
| FY2016 | -0.5% | -100.5% |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026